IRMD - Earnings announcements

Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance  Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)

ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time

Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025, which are increases of 25% and 23%, respectively, compared to the same period in 2024. Reports record GAAP diluted EPS of $1.75 and non-GAAP diluted EPS of $1.93 for the full year of 2025, which are increases of 17% and 16%, respectively, compared to the full year of 2024. Declares a regular quarterly cash dividend of $0.20 per share of common stock for the fourth quarter of 2025, payable on March 6, 2026. ORLANDO, Fla., Feb. 10, 2026 (G

ORLANDO, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 fourth quarter and full year financial results before the market opens on Tuesday, February 10, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI9eabdb5f5ea54652b0bd15ed7530706e. Once registered, a dial-in number, unique pin, and instructions will be provided to participants.The conference call will also be

Reports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024.Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025. ORLANDO, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BIb4c35afb95154b348a034716bd7b99d8. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025. ORLANDO, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI52cf21ec526142b8b6142d07c87cfcf9. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available re

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adffOnce registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-

Reports record revenue of $19.4 million for the fourth quarter of 2024, an increase of $1.9 million or 11%, compared to the same period in 2023. Reports GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44 for the fourth quarter of 2024.Reports GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66 for the full year of 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the first quarter of 2025, payable on March 5, 2025. WINTER SPRINGS, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial

WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BI94f1f3be82df46ccb09997e06cb41e49Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-ti

Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023.Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024, payable on November 25, 2024. WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial result

WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIb21de778973841f8add41c2c49939c39. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be avail

Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023.Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024.Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023. Declares a regular quarterly cash dividend of $0.15 per common share for the third quarter of 2024, payable on August 30, 2024. WINTER SPRINGS, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and six months ended June 30, 2024. The Com

Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIa6da8f185c0d4199a6c370fbe9fba158. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-tim

Reports record revenue of $17.6 million for the first quarter of 2024.Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024.Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023.Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024. WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI

WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIa8e7a7f6a1a54f62b666af525d8cefcc. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-ti

Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023. Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022 and full-year operating income of $20.0 million, an increase of 28.2%, compared to the same period in 2022. WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three m

WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIc7cd4e26433141619fd5dc96c9970143.Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-tim

Reports record revenue of $16.5 million for the third quarter of 2023.GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43.Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022. WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and nine months ended September 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that ar

WINTER SPRINGS, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2023 third quarter financial results before the market opens on Friday, November 3rd. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BI128479408327463f9d559a793be4df6a.Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time via

Reports record revenue of $16.1 million for the second quarter of 2023GAAP diluted EPS of $0.33 and non-GAAP diluted EPS of $0.36Operating income was $5.0 million and increased by 19%Announces third quarter and full year 2023 financial guidance WINTER SPRINGS, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), announced today its financial results for the three and six months ended June 30, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that

WINTER SPRINGS, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2023 second quarter financial results before the market opens on Thursday, August 3rd. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BI5637da83c25e4c57a097826fce806954.Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time

Reports record revenue of $15.5 million for the first-quarter quarter of 2023 GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30 Operating income was $4.0 million and increased by 30% Announces second quarter 2023 financial guidance and increases full-year 2023 financial guidance WINTER SPRINGS, Fla., May 04, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), announced today its financial results for the three months ended March 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic pati

WINTER SPRINGS, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2023 first quarter financial results before the market opens on Thursday, May 4th. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIcf1e7c2140024a1c8d825b18c82691f0. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time via t

Reports fourth quarter 2022 revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32.Reports full-year 2022 revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10.The Board of Directors approved a special cash dividend of $1.05 per share. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. WINTER SPRINGS, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the fourth quarter and year ended December 31, 2022. The Company also announced that its Board of Directors approved

WINTER SPRINGS, Fla., Jan. 26, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2022 fourth quarter financial results before the market opens on Thursday, February 2, 2023.  IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. IRADIMED has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time Thursday, February 2, 2023. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIf5d19937b47e482a9911d79a50a0a05b Once registe

Revenue was $13.4 million and increased by 23%Operating income was $4.1 million and increased 32%GAAP diluted EPS was $0.27 and increased by 35%Announces fourth quarter 2022 financial guidance WINTER SPRINGS, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its financial results for the three and nine months ended September 30, 2022. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system and non-magnetic patient vital signs monitoring systems designed for use during MRI procedures. "This quarte

WINTER SPRINGS, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2022 third quarter financial results before the market opens on Thursday, November 3rd. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. IRADIMED has scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time Thursday, November 3, 2022. Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIcffe00ca21c54c31b6a2a7db74cb48ea.Once registered,

Reports second quarter 2022 revenue of $12.7 million, GAAP diluted EPS of $0.26 and non-GAAP diluted EPS of $0.26Announces third quarter 2022 financial guidance WINTER SPRINGS, Fla., July 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), announced today its financial results for the three and six months ended June 30, 2022. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures. "It is with great satisfaction that we

WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by registering here https://register.vevent.com/register/BI3271df296f5d41f5a8b888dee69b451c.Once registered, a dial-in number and unique pin will be provided to dial in. The conference call will also be available real-time via the Internet at htt

Reports first quarter 2022 revenue of $12.3 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.22Announces second quarter 2022 financial guidanceIncreases full-year 2022 financial guidance WINTER SPRINGS, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), announced today its financial results for the three months ended March 31, 2022. The Company is a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI p

WINTER SPRINGS, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 3179386. The conference call will also be available real-time via the Internet at http://www.iradimed.com/en-us/investors/

Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33Announces full-year and first quarter 2022 financial guidance WINTER SPRINGS, Fla., Feb. 04, 2022 (GLOBE NEWSWIRE) --  iRadimed Corporation (the "Company") (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three months and year ended December 31, 2021. "I am very happy to report these r

WINTER SPRINGS, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2021 fourth quarter financial results before the market opens on Friday, February 4th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 2899922. The conference call will also be available real-time via the Internet at http://www.iradimed.com/en-us/investors/events

Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23Increases full-year 2021 financial guidance WINTER SPRINGS, Fla., Oct. 29, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three and nine months ended September 30, 2021. "I am pleased with these financial re

WINTER SPRINGS, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2021 third quarter financial results before the market opens on Friday, October 29th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 1675895. The conference call will also be available real-time via the Internet at http://www.iradimed.com/en-us/investors/events/

Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14Issues Q3 and full year 2021 financial guidance WINTER SPRINGS, Fla., July 30, 2021 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD), a leader in the development of innovative magnetic resonance imaging ("MRI") medical devices and the only known provider of a non-magnetic intravenous ("IV") infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three and six months ended June 30, 2021. "This quarter marks another record high in total bookings f